Pharmacovigilance study and genetic target prediction analysis of FDA adverse event reporting system for anticancer drug-associated interstitial lung disease | Synapse
March 3, 2026
Pharmacovigilance study and genetic target prediction analysis of FDA adverse event reporting system for anticancer drug-associated interstitial lung disease
Key Points
Interstitial lung disease is a significant adverse event associated with certain anticancer drugs, indicating potential genetic links.
The analysis emphasizes pharmacovigilance as a crucial method for understanding drug safety and identifying genetic targets.
Results from FDA data reveal how genetic target prediction can improve monitoring of adverse events for safer treatments.
Findings suggest the need for enhanced pharmacovigilance efforts in recognizing and preventing drug-induced lung diseases.